Augmentin (BD) (amoxicillin) coated tablets 875/125 mg. №14

Augmentin (BD) (amoxicillin) coated tablets 875/125 mg. №14

$32.30

Manufacturer: UK

Augmentin (BD) tablets contain 875 mg amoxicillin and 125 mg clavulanic acid, used to treat bacterial infections:

  • acute bacterial sinusitis (confirmed)
  • acute otitis media,
  • confirmed exacerbation of chronic bronchitis;
  • community-acquired pneumonia
  • cystitis;
  • pyelonephritis;
  • infections of the skin and soft tissues, including cellulitis, animal bites, severe odontogenic abscesses with widespread cellulitis;
  • infections of bones and joints, including osteomyelitis.
Category:

Description

Augmentin (BD) (amoxicillin) tablets 875 mg / 125 mg, 14 pcs. – Instructions for use

Ingredients

active ingredients:  amoxicillin and clavulanic acid;

1 tablet contains amoxicillin (in the form of amoxicillin trihydrate) 875 mg, clavulanic acid (in the form of potassium clavulanate) 125 mg;

excipients : magnesium stearate, sodium starch (type A), colloidal silicon dioxide, microcrystalline cellulose, dimethicone;

tablet shell:  titanium dioxide (E 171), hypromellose (5 cps), hypromellose (15 cps), macrogol 4000, macrogol 6000.

Dosage form

Film-coated tablets.

Basic physical and chemical properties:  capsule-shaped white or off-white film-coated tablets with a break line on one side and P monograms on both sides.

Pharmacotherapeutic group

Antibacterial agents for systemic use. Beta-lactam antibiotics, penicillins. Combinations of penicillins with beta-lactamase inhibitors.

ATX code J01C R02.

Pharmacodynamics

Mechanism of action

Amoxicillin is a semi-synthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) during the biosynthetic metabolism of bacterial peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, resulting in cell lysis and death.

Amoxicillin is sensitive to the breakdown of beta-lactamases produced by resistant bacteria, therefore, the spectrum of activity of amoxicillin as a monotherapy does not include microorganisms that produce these enzymes.

Clavulanic acid is a beta-lactam structurally related to penicillins. It disables some of the beta-lactamase enzymes, thereby preventing the inactivation of amoxicillin. Clavulanic acid alone does not provide a clinically useful antibacterial effect.

Indications

Treatment in adults and children of bacterial infections caused by microorganisms sensitive to Augmentin:

  • acute bacterial sinusitis (confirmed)
  • acute otitis media,
  • confirmed exacerbation of chronic bronchitis;
  • community-acquired pneumonia
  • cystitis;
  • pyelonephritis;
  • infections of the skin and soft tissues, including cellulitis, animal bites, severe odontogenic abscesses with widespread cellulitis;
  • infections of bones and joints, including osteomyelitis.

When prescribing antibacterial drugs, one should be guided by the rules for their proper use.

Contraindications

Hypersensitivity to the components of the drug, to any antibacterial agents of the penicillin group.

A history of severe hypersensitivity reactions (including anaphylaxis) associated with the use of other β-lactam agents (including cephalosporins, carbapenems, or monobactams).

A history of jaundice or liver dysfunction associated with the use of amoxicillin/clavulanate.

Dosage and administration

Dosage expressed in terms of the content of amoxicillin / clavulanic acid, except when the dosage is expressed in terms of a single component.

When choosing the dosage of Augmentin for the treatment of a particular infection, the following should be considered:

  • probable causative agents of the disease and their possible sensitivity to antibacterial drugs;
  • the severity and location of the infection;
  • age, body weight, and renal function of the patient, as indicated below.

If necessary, consider using alternative forms of release of Augmentin (that is, providing high doses of amoxicillin and / or different ratios of the content of amoxicillin and clavulanic acid).

For adults and children weighing ≥ 40 kg, the total daily dose is 1750 mg amoxicillin / 250 mg clavulanic acid (2 tablets), the daily dose is divided into 2 doses. For children weighing <40 kg, the maximum daily dose is 1000-2800 mg amoxicillin / 143-400 mg clavulanic acid when administered as indicated below.

If large doses of amoxicillin must be prescribed for treatment, other forms of Augmentin should be used to avoid prescribing unnecessary high doses of clavulanic acid.

The duration of treatment is determined by the patient’s clinical response to treatment. Some infections (such as osteomyelitis) require long-term treatment. Treatment should not be continued for more than 14 days without revision.

Adults and children weighing ≥ 40 kg

Recommended standard dose (for all indications): 875 mg / 125 mg 2 times a day.

Children weighing 25 to 40 kg

Treatment can be carried out with Augmentin in the form of tablets or suspensions.

Recommended doses:

  • 25 mg / 3.6 mg / kg / day to 45 mg / 6.4 mg / kg / day, divided into 2 doses;
  • for the treatment of certain infections (such as otitis media, sinusitis, and lower respiratory tract infections), up to 70 mg / 10 mg / kg / day, divided into 2 doses, can be used.

Since the tablet cannot be divided, for children weighing less than 25 kg, this form of Augmentin is not prescribed.

The table below shows the dose in mg / kg of body weight that a child weighing from 25 kg to 40 kg receives when using one tablet of Augmentin 875/125 mg.

Body weight (kg)

40

35

thirty

25

Recommended single dose (mg/kg body weight)

(see above)

The amount of amoxicillin (mg / kg body weight) when taking a single dose is 1 tablet

Augmentin 875/125 mg

21.9

25.0

29.2

35.0

12.5–22.5

(not higher than 35)

The amount of clavulanic acid (mg / kg body weight) when taking a single dose is 1 tablet of Augmentin 875/125 mg

3.1

3.6

4.2

5.0

1.8–3.2

(not higher than 5)

For children weighing less than 25 kg, it is advisable to prescribe Augmentin treatment in the form of a suspension.

There are no clinical data on the use of dosage forms of Augmentin 7: 1, exceeding 45 mg / 6.4 mg / kg of body weight per day, for children under 2 years of age.

There are no clinical data on the use of dosage forms of Augmentin 7: 1 in children under 2 months. Therefore, there are no recommendations regarding dosing for this group of patients.

Elderly patients

Dose adjustment is not required.

Dosing for impaired renal function

Patients with a creatinine clearance (CrCl) of 30 ml/min do not require dose adjustment. Patients with creatinine clearance less than 30 ml / min are recommended to use Augmentin dosage forms with a ratio of amoxicillin and clavulanic acid of 7: 1, since there are no recommendations for dose adjustment.

Dosage in violation of liver function.

Apply with caution, it is necessary to monitor liver function at regular intervals.

Mode of application

The drug is intended for oral use.

The tablet should be swallowed whole without chewing. If necessary, the tablet can be broken in half and swallowed in half without chewing.

The drug Should be taken with meals to minimize potential gastrointestinal intolerance.

Therapy can be started with parenteral administration, according to the instructions for use of the injection form of Augmentin, and continue with oral forms.

Related products